COVID-19 Vaccines – FDA authorizes Moderna, Janssen boosters and “mix and match” vaccines

- On October 20, 2021, the FDA authorized booster doses for Moderna and Janssen’s COVID-19 vaccines for certain populations. In addition, the FDA authorized heterologous (or mix and match) booster doses for each of the available COVID-19 vaccines.

- The FDA has amended the emergency use authorization (EUA) for the Moderna COVID-19 vaccine to allow for use of a single booster dose of mRNA-1273 at 50 mcg to be administered at least six months after completion of the primary series. The eligible population includes:

    — Individuals 65 years of age and older;
    — Individuals 18 through 64 years of age at high risk of severe COVID-19; and
    — Individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

- The Moderna COVID-19 vaccine booster is approved for the same populations as the Pfizer-BioNTech COVID-19 vaccine booster.

- The FDA has amended the EUA for the Janssen COVID-19 vaccine to allow for use of a single booster dose of Janssen COVID-19 vaccine to be administered at least 2 months after primary vaccination with the Janssen COVID-19 vaccine, to individuals 18 years of age and older.

- The FDA has amended the EUAs for Pfizer, Moderna and Janssen’s COVID-19 vaccines to allow for a single booster dose to be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination.